# A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis

> **NCT07321873** · PHASE2 · RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 240 (estimated)

## Conditions studied

- Arthritis, Psoriatic

## Interventions

- **DRUG:** JNJ-88545223
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07321873
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-15
- **Primary completion:** 2027-06-28
- **Final completion:** 2027-08-02
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07321873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07321873, "A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT07321873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*